+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Familial Adenomatous Polyposis Treatment Market by Type (Aspirin, CEQ-508, Eflornithine Hydrochloride), End-Users (Clinics & Hospitals, Diagnostic Centres, Home Healthcare), Distribution Channel - Forecast 2024-2030

  • PDF Icon

    Report

  • 184 Pages
  • June 2024
  • Region: Global
  • 360iResearch™
  • ID: 5967598
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Familial Adenomatous Polyposis Treatment Market grew from USD 1.12 billion in 2023 to USD 1.20 billion in 2024. It is expected to continue growing at a CAGR of 7.43%, reaching USD 1.85 billion by 2030.

This genetic disorder increases the risk of developing colorectal cancer significantly if left untreated. The objective of FAP treatment is not only to manage symptoms and prevent the development of colorectal cancer but also to maintain the quality of life for those with the condition. Treatment plans are often personalized to fit the needs and circumstances of the individual patient, focusing on minimizing potential risks and complications associated with the disease. Growing awareness among populations and improvements in genetic testing have led to earlier and increased diagnoses, expanding the need for treatment options such as FAP treatment. As colorectal cancer rates rise globally, there is a growing emphasis on preventive treatments for conditions like FAP that significantly raise cancer risk. However, concerns associated with the side effects of FAP medicines, along with the regulatory hurdles, present a significant challenge for the companies. Conversely, investment in the research and development of new drugs and less invasive surgical techniques could significantly advance treatment options. The rise of genetic counseling and personalized medicine approaches offers opportunities to tailor treatments to individual genetic profiles, potentially improving outcomes.

Regional Insights

In the Americas, the United States and Canada are at the forefront of FAP research and treatment, with several patented technologies and innovative therapeutic approaches being developed in both countries. America's strong regulatory framework, facilitated by the FDA, supports extensive research and fast-tracking promising treatments. Both countries ' public and private healthcare systems enable a relatively high level of patient awareness and access to advanced treatment options. At the same time, in EMEA, the patients benefit from a harmonized regulatory environment, which aids in the swift adoption of new treatments. Cross-national collaborations often support research initiatives, such as those facilitated by the European Medicines Agency (EMA). High standards of healthcare and widespread awareness among populations contribute to the effective management and treatment of FAP. Moreover, the Asia Pacific region is experiencing rapid growth in healthcare capabilities, with China, Japan, and India significant in research and treatment development for FAP. Given its robust pharmaceutical and biotechnology sectors, there's a significant focus on genetic research and the development of targeted therapies in Japan. India is becoming more adept at diagnosing and treating hereditary conditions such as FAP. China's vast population and investment in healthcare innovation have also made it a key player in the region.

Market Insights

Market Dynamics

  • The market dynamics represent an ever-changing landscape of the Familial Adenomatous Polyposis Treatment Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

  • Growing concerns related to genetic disorders among populations and the need for effective treatment options
  • Favorable government initiatives and reimbursement policies for colorectal cancer

Market Restraints

  • Strict governments regulations for FAP drugs and cases of product recalls

Market Opportunities

  • Rapid pace of technological innovation in genetic testing and drug delivery system
  • Investment in the research and development of new drugs and less invasive surgical techniqe

Market Challenges

  • Risk of significant side effects associated with the FAP medicines

Market Segmentation Analysis

  • Type: Growing preference for icosapent and aspirin as an anti-inflammatory medications in Familial Adenomatous Polyposis (FAP) treatment
  • End-Users: Widening availability of Familial Adenomatous Polyposis treatment options through hospitals and diagnostic centers

Industry Insights

  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Familial Adenomatous Polyposis Treatment Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Familial Adenomatous Polyposis Treatment Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Breakthrough Treatment for Desmoid Tumors Receives FDA Approval

The U.S. Food and Drug Administration (FDA) has officially approved Nirogacestat, a significant advancement for adult patients battling desmoid tumors. Desmoid tumors, which can arise in various parts of the body and tend to recur, have previously had limited treatment options. Nirogacestat, an oral therapy, is pivotal in managing these challenging tumors. By offering a non-invasive treatment alternative, Nirogacestat signifies hope for improved patient outcomes and highlights the progress in personalized cancer therapy. This approval underscores the FDA’s commitment to fostering innovative treatments for complex diseases, promising a new horizon for patients and their families facing the trials of desmoid tumors.

FDA Grants Orphan-Drug Designation to Therapyx's FAPXIL for Familial Adenomatous Polyposis Treatment

The United States Food and Drug Administration's (FDA) Office of Orphan Product Development has awarded Therapyx's experimental therapy, FAPXIL, with orphan-drug status for Familial Adenomatous Polyposis (FAP) treatment. FAP, a genetically inherited condition marked by the emergence of numerous adenomas in the colon and rectum, typically during adolescence, affects roughly 1 in 8,300 individuals at birth and impacts up to 50,000 Americans, irrespective of gender. This condition currently has no cure, making the development of FAPXIL a pivotal step in addressing the unmet medical needs of those living with FAP.

Groundbreaking Clinical Trial for Familial Adenomatous Polyposis Receives FDA Go-Ahead

Eloxx Pharmaceuticals has obtained approval from the U.S. Food and Drug Administration (FDA) to commence a clinical trial aimed at tackling Familial Adenomatous Polyposis (FAP), a precancerous condition marked by the development of numerous polyps in the colon and rectum. The trial's approval underscores a critical advancement in clinical research, spotlighting Eloxx Pharmaceuticals' commitment to addressing unmet medical needs through innovative therapeutic approaches. This development represents a beacon of hope for patients grappling with FAP, offering a potential pathway to manage and possibly curtail the progression of this challenging condition.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Familial Adenomatous Polyposis Treatment Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Familial Adenomatous Polyposis Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Ambry Genetics Corporation, Amgen Inc., AstraZeneca PLC, Cellix Bio, Chugai Pharmaceutical Co., Ltd., Eli Lilly and Company, Eloxx Pharmaceuticals Inc., Emtora Biosciences, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Novartis AG, Panbela Therapeutics Inc., Pfizer Inc., Sanofi SA, Simson Pharma, SLA Pharma AG, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Familial Adenomatous Polyposis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type

  • Aspirin
  • CEQ-508
  • Eflornithine Hydrochloride
  • Icosapent

End-Users

  • Clinics & Hospitals
  • Diagnostic Centres
  • Home Healthcare

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy

Region

Americas

  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
  • California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas

Asia-Pacific

  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam

Europe, Middle East & Africa

  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing concerns related to genetic disorders among populations and the need for effective treatment options
5.1.1.2. Favorable government initiatives and reimbursement policies for colorectal cancer
5.1.2. Restraints
5.1.2.1. Strict governments regulations for FAP drugs and cases of product recalls
5.1.3. Opportunities
5.1.3.1. Rapid pace of technological innovation in genetic testing and drug delivery system
5.1.3.2. Investment in the research and development of new drugs and less invasive surgical techniqe
5.1.4. Challenges
5.1.4.1. Risk of significant side effects associated with the FAP medicines
5.2. Market Segmentation Analysis
5.2.1. Type: Growing preference for icosapent and aspirin as an anti-inflammatory medications in Familial Adenomatous Polyposis (FAP) treatment
5.2.2. End-Users: Widening availability of Familial Adenomatous Polyposis treatment options through hospitals and diagnostic centers
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Familial Adenomatous Polyposis Treatment Market, by Type
6.1. Introduction
6.2. Aspirin
6.3. CEQ-508
6.4. Eflornithine Hydrochloride
6.5. Icosapent
7. Familial Adenomatous Polyposis Treatment Market, by End-Users
7.1. Introduction
7.2. Clinics & Hospitals
7.3. Diagnostic Centres
7.4. Home Healthcare
8. Familial Adenomatous Polyposis Treatment Market, by Distribution Channel
8.1. Introduction
8.2. Hospital Pharmacy
8.3. Retail Pharmacy
9. Americas Familial Adenomatous Polyposis Treatment Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Familial Adenomatous Polyposis Treatment Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Familial Adenomatous Polyposis Treatment Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.3.1. Breakthrough Treatment for Desmoid Tumors Receives FDA Approval
12.3.2. FDA Grants Orphan-Drug Designation to Therapyx's FAPXIL for Familial Adenomatous Polyposis Treatment
12.3.3. Groundbreaking Clinical Trial for Familial Adenomatous Polyposis Receives FDA Go-Ahead
12.4. Strategy Analysis & Recommendation
13. Competitive Portfolio
13.1. Key Company Profiles
13.2. Key Product Portfolio
List of Figures
FIGURE 1. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET DYNAMICS
FIGURE 7. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
FIGURE 10. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 12. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 22. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ASPIRIN, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ASPIRIN, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY CEQ-508, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY CEQ-508, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY EFLORNITHINE HYDROCHLORIDE, BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY EFLORNITHINE HYDROCHLORIDE, BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ICOSAPENT, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ICOSAPENT, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY CLINICS & HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY CLINICS & HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DIAGNOSTIC CENTRES, BY REGION, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DIAGNOSTIC CENTRES, BY REGION, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2024-2030 (USD MILLION)
TABLE 31. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 32. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 33. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 34. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 35. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 36. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 37. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 38. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 39. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 40. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 41. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 42. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 43. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 44. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 45. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 46. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 47. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 48. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 49. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 50. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 51. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 52. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 53. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 54. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 55. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 56. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 57. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 58. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 59. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 60. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 61. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 62. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 63. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 64. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 65. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 66. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 67. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 68. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 69. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 70. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 71. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 72. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 73. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 74. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 76. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 78. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 79. AUSTRALIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 80. AUSTRALIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 81. AUSTRALIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 82. AUSTRALIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 83. AUSTRALIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 84. AUSTRALIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 85. CHINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 86. CHINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 87. CHINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 88. CHINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 89. CHINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 90. CHINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 91. INDIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 92. INDIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 93. INDIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 94. INDIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 95. INDIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 96. INDIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 97. INDONESIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 98. INDONESIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 99. INDONESIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 100. INDONESIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 101. INDONESIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 102. INDONESIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 103. JAPAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 104. JAPAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 105. JAPAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 106. JAPAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 107. JAPAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 108. JAPAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 109. MALAYSIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 110. MALAYSIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 111. MALAYSIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 112. MALAYSIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 113. MALAYSIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 114. MALAYSIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 115. PHILIPPINES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 116. PHILIPPINES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 117. PHILIPPINES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 118. PHILIPPINES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 119. PHILIPPINES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 120. PHILIPPINES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 121. SINGAPORE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 122. SINGAPORE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 123. SINGAPORE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 124. SINGAPORE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 125. SINGAPORE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 126. SINGAPORE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 127. SOUTH KOREA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 128. SOUTH KOREA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 129. SOUTH KOREA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 130. SOUTH KOREA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 131. SOUTH KOREA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 132. SOUTH KOREA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 133. TAIWAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 134. TAIWAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 135. TAIWAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 136. TAIWAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 137. TAIWAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 138. TAIWAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 139. THAILAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 140. THAILAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 141. THAILAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 142. THAILAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 143. THAILAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 144. THAILAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 145. VIETNAM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 146. VIETNAM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 147. VIETNAM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 148. VIETNAM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 149. VIETNAM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 150. VIETNAM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 159. DENMARK FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 160. DENMARK FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 161. DENMARK FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 162. DENMARK FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 163. DENMARK FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 164. DENMARK FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 165. EGYPT FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 166. EGYPT FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 167. EGYPT FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 168. EGYPT FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 169. EGYPT FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 170. EGYPT FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 171. FINLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 172. FINLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 173. FINLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 174. FINLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 175. FINLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 176. FINLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 177. FRANCE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 178. FRANCE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 179. FRANCE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 180. FRANCE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 181. FRANCE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 182. FRANCE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 183. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 184. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 185. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 186. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 187. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 188. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 189. ISRAEL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 190. ISRAEL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 191. ISRAEL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 192. ISRAEL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 193. ISRAEL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 194. ISRAEL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 195. ITALY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 196. ITALY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 197. ITALY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 198. ITALY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 199. ITALY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 200. ITALY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 201. NETHERLANDS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 202. NETHERLANDS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 203. NETHERLANDS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 204. NETHERLANDS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 205. NETHERLANDS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 206. NETHERLANDS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 207. NIGERIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 208. NIGERIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 209. NIGERIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 210. NIGERIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 211. NIGERIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 212. NIGERIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 213. NORWAY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 214. NORWAY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 215. NORWAY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 216. NORWAY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 217. NORWAY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 218. NORWAY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 219. POLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 220. POLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 221. POLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 222. POLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 223. POLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 224. POLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 225. QATAR FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 226. QATAR FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 227. QATAR FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 228. QATAR FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 229. QATAR FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 230. QATAR FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 231. RUSSIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 232. RUSSIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 233. RUSSIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 234. RUSSIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 235. RUSSIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 236. RUSSIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 238. SAUDI ARABIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 240. SAUDI ARABIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 242. SAUDI ARABIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 244. SOUTH AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 246. SOUTH AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 248. SOUTH AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 249. SPAIN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 250. SPAIN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 251. SPAIN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 252. SPAIN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 253. SPAIN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 254. SPAIN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 255. SWEDEN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 256. SWEDEN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 257. SWEDEN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 258. SWEDEN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 259. SWEDEN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 260. SWEDEN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 261. SWITZERLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 262. SWITZERLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 263. SWITZERLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 264. SWITZERLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 265. SWITZERLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 266. SWITZERLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 267. TURKEY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 268. TURKEY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 269. TURKEY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 270. TURKEY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 271. TURKEY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 272. TURKEY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 280. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 282. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 284. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 285. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
TABLE 286. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AbbVie Inc.
  • Ambry Genetics Corporation
  • Amgen Inc.
  • AstraZeneca PLC
  • Cellix Bio
  • Chugai Pharmaceutical Co., Ltd.
  • Eli Lilly and Company
  • Eloxx Pharmaceuticals Inc.
  • Emtora Biosciences
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Panbela Therapeutics Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Simson Pharma
  • SLA Pharma AG
  • Takeda Pharmaceutical Company
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages184
PublishedJune 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 1.2 Billion
Forecasted Market Value ( USD ) by 2030 $ 1.85 Billion
Compound Annual Growth Rate7.4%
Regions CoveredGlobal

Related Topics

Related Reports

Familial Adenomatous Polyposis - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Familial Adenomatous Polyposis - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Familial Adenomatous Polyposis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Familial Adenomatous Polyposis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 138 Pages
  • Global
From
Familial Adenomatous Polyposis - Pipeline Insight, 2024 - Product Image

Familial Adenomatous Polyposis - Pipeline Insight, 2024

  • Clinical Trials
  • 50 Pages
  • Global
From
Adenomatous Polyposis Coli Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Adenomatous Polyposis Coli Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 130 Pages
  • Global
From
Colorectal Cancer Diagnosis and Therapeutic Updates - Product Image

Colorectal Cancer Diagnosis and Therapeutic Updates

  • Book

About the Familial Adenomatous Polyposis Drug Market

Familial Adenomatous Polyposis (FAP) is a rare genetic disorder that causes the formation of numerous polyps in the colon. These polyps can become cancerous if left untreated. As such, drugs used to treat FAP are important in the treatment of colon cancer. These drugs are typically targeted therapies, which are designed to specifically target the genetic mutation that causes FAP. Commonly used drugs include bevacizumab, cetuximab, and panitumumab. These drugs are used in combination with other treatments such as chemotherapy and radiation therapy. The Familial Adenomatous Polyposis Drug market is a small but growing market. It is driven by the increasing prevalence of FAP and the need for effective treatments. The market is expected to grow in the coming years as new treatments are developed and approved. Some companies in the market include Roche, Merck, Pfizer, and Bristol-Myers Squibb. These companies are involved in the development and marketing of drugs used to treat FAP. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.